159 related articles for article (PubMed ID: 19399271)
1. Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.
Yoon JH; Park JA; Kim EK; Kang HJ; Shin HY; Ahn HS
J Korean Med Sci; 2009 Apr; 24(2):281-8. PubMed ID: 19399271
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
3. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
4. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
5. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
6. Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Giona F; Annino L; Testi AM; Rondelli R; Arcese W; Meloni G; Moleti ML; Mandelli F
Leuk Lymphoma; 1998 Dec; 32(1-2):89-95. PubMed ID: 10037004
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
8. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
Giona F; Testi AM; Amadori S; Meloni G; Carotenuto M; Resegotti L; Colella R; Leoni P; Carella AM; Grotto P
Ann Oncol; 1990; 1(1):51-5. PubMed ID: 2078485
[TBL] [Abstract][Full Text] [Related]
10. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F
Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Willemze R; Suciu S; Archimbaud E; Muus P; Stryckmans P; Louwagie EA; Berneman Z; Tjean M; Wijermans P; Dohner H; Jehn U; Labar B; Jaksic B; Dardenne M; Zittoun R
Leukemia; 1997 Mar; 11 Suppl 1():S24-7. PubMed ID: 9130688
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
13. RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.
Saarinen-Pihkala UM; Parto K; Riikonen P; Lähteenmäki PM; Békàssy AN; Glomstein A; Möttönen M
J Pediatr Hematol Oncol; 2012 May; 34(4):263-70. PubMed ID: 22246158
[TBL] [Abstract][Full Text] [Related]
14. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
15. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.
O'Brien TA; Russell SJ; Vowels MR; Oswald CM; Tiedemann K; Shaw PJ; Lockwood L; Teague L; Rice M; Marshall GM;
Blood; 2002 Oct; 100(8):2708-16. PubMed ID: 12351376
[TBL] [Abstract][Full Text] [Related]
16. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
17. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.
Testi AM; Del Giudice I; Arcese W; Moleti ML; Giona F; Basso G; Biondi A; Conter V; Messina C; Rondelli R; Micozzi A; Micalizzi C; Barisone E; Locatelli F; Dini G; Aricò M; Casale F; Comis M; Ladogana S; Lippi A; Mura R; Pinta MF; Santoro N; Valsecchi MG; Masera G; Mandelli F;
Br J Haematol; 2002 Sep; 118(3):741-7. PubMed ID: 12181040
[TBL] [Abstract][Full Text] [Related]
18. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
19. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica.
Giona F; Testi AM; Annino L; Amadori S; Arcese W; Camera A; Di Montezemolo LC; Ladogana S; Liso V; Meloni G
Br J Haematol; 1994 Jan; 86(1):55-61. PubMed ID: 8011548
[TBL] [Abstract][Full Text] [Related]
20. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
